quinagolide vaginal ring (FE-999051)
/ Ferring
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
April 07, 2025
Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial.
(PubMed, Eur J Obstet Gynecol Reprod Biol)
- P2 | "Our primary analysis showed no significant difference between treatment groups in terms of change in total lesion size. Many patients in this study presented with advanced disease, which may be less responsive to quinagolide than highly vascularized superficial lesions, as quinagolide inhibits the VEGF signaling pathway."
Clinical • Journal • Endometriosis • Gynecology • Pain • Women's Health • PRL
October 04, 2022
RAQUEL: Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
(clinicaltrials.gov)
- P2 | N=22 | Completed | Sponsor: Ferring Pharmaceuticals | Active, not recruiting ➔ Completed | Trial completion date: Aug 2023 ➔ Feb 2022
Trial completion • Trial completion date • Endometriosis • Gynecology • Pain • Women's Health • IGF1
April 04, 2022
RAQUEL: Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
(clinicaltrials.gov)
- P2 | N=22 | Active, not recruiting | Sponsor: Ferring Pharmaceuticals | Trial primary completion date: Jul 2023 ➔ Feb 2022
Trial primary completion date • Endometriosis • Gynecology • Pain • IGF1
November 18, 2021
RAQUEL: Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
(clinicaltrials.gov)
- P2; N=22; Active, not recruiting; Sponsor: Ferring Pharmaceuticals; Recruiting ➔ Active, not recruiting; N=280 ➔ 22
Clinical • Enrollment change • Enrollment closed • Endometriosis • Gynecology • Pain • IGF1
August 04, 2021
QLARITY: Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
(clinicaltrials.gov)
- P2; N=67; Completed; Sponsor: Ferring Pharmaceuticals; Active, not recruiting ➔ Completed
Trial completion • Endometriosis • Gynecology • Women's Health • IGF1 • MRI
1 to 5
Of
5
Go to page
1